Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Acquires Diagnostic Shop Genaco for $22M in Cash

NEW YORK (GenomeWeb News) — Qiagen last week acquired Genaco Biomedical Products for $22 million in cash, the company said today.
 
Qiagen purchased 100 percent of the company’s outstanding stock, and will pay out as much as $18 million in milestone payments from anticipated grants.  
 
Genaco is an early-stage company that uses a proprietary PCR-based multiplexing technology, called TEM-PCR, in its Templex molecular diagnostics, Qiagen said.
 
These tests are used by medical researchers to investigate respiratory, nosocomial bacterial infections, and other pathogens.
 
Qiagen said it expects the acquisition to contribute approximately $200,000 in sales in the fourth quarter of 2006 and approximately $3 million in sales for the full year of 2007.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.